<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03571789</url>
  </required_header>
  <id_info>
    <org_study_id>CL-150</org_study_id>
    <nct_id>NCT03571789</nct_id>
  </id_info>
  <brief_title>Carotid Artery Implant for Trapping Upstream Emboli for Preventing Stroke in Atrial Fibrillation Patients</brief_title>
  <acronym>CAPTURE</acronym>
  <official_title>Carotid Artery Implant for Trapping Upstream Emboli for Preventing Stroke in Atrial Fibrillation Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Javelin Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Javelin Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vine™ is a permanent carotid filter designed to provide protection against embolic stroke in&#xD;
      people with atrial fibrillation. It is implanted bilaterally in the common carotid arteries&#xD;
      from a thin needle under ultrasound guidance. The procedure is performed without general&#xD;
      anesthesia and takes minutes. The safety, feasibility and tolerability of Vine™ will be&#xD;
      evaluated. Patients who are eligible will receive Vine™ and will be followed-up for a year&#xD;
      after device implantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CAPTURE is a prospective, single-arm, multicenter trial, designed to evaluate the safety,&#xD;
      feasibility and tolerability of the Vine™ permanent carotid filter. The trial will enroll up&#xD;
      to 30 patients, and will be conducted in up to five sites worldwide. All enrolled patients&#xD;
      will be invited for non-invasive follow-up tests and clinical evaluations according to the&#xD;
      study protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 12, 2017</start_date>
  <completion_date type="Anticipated">November 13, 2022</completion_date>
  <primary_completion_date type="Actual">December 13, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Multicenter, prospective, non-randomized, open-label, first-in-human (FIH) study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with no incidence of device and/or procedure related Major Adverse Events (MAEs)</measure>
    <time_frame>30 days from implantation procedure</time_frame>
    <description>Major Adverse Events (MAEs) are defined as:&#xD;
Death&#xD;
Major and minor strokes&#xD;
Major bleeding&#xD;
Common carotid artery (CCA) stenosis &gt; 70%&#xD;
Vine™ migration&#xD;
CCA thrombus&#xD;
Any complications in the CCA requiring endovascular treatment or surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with Procedure Success</measure>
    <time_frame>30 days from implantation procedure</time_frame>
    <description>Procedure Success is defined as Proper Vine™ Position in each CCA&#xD;
Proper Vine™ Position is defined as:&#xD;
Supporting coil in contact with artery walls&#xD;
No migration&#xD;
No fracture&#xD;
No Vine™ coils or portions thereof visible outside the arterial lumen&#xD;
No entangled or overlapping coils</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with no incidence of device and/or procedure related Major Adverse Events (MAEs)</measure>
    <time_frame>within 3, 6, months,1, 2, 3, 4 and 5 years of implantation procedure</time_frame>
    <description>Death&#xD;
Major and minor strokes&#xD;
Major bleeding&#xD;
Common carotid artery (CCA) stenosis &gt; 70%&#xD;
Vine™ migration&#xD;
CCA thrombus&#xD;
Any complications in the CCA requiring endovascular treatment or surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Successful Delivery and Deployment Attempts</measure>
    <time_frame>within 4 hours of implantation procedure</time_frame>
    <description>Successful Delivery and Deployment Attempts is defined as Proper Vine™ Position</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with properly positioned Vine™ in each CCA</measure>
    <time_frame>within 3, 6, months,1, 2, 3, 4 and 5 years of implantation procedure</time_frame>
    <description>Proper implant position</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Vine™ implantation bilaterally in the common carotid arteries</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vine™ is a permanent carotid filter made from a single nitinol wire. It is configured to capture emboli exceeding 1.2mm in size, which originate in the heart and large arteries below the neck. Vine™ has a helical structure, with leading and supporting coils interposed by a filter section.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vine™</intervention_name>
    <description>The Vine™ is made of a super-elastic nitinol wire comprises a helix that resides within the CCA lumen and a linear stem that traverses the CCA wall. The helix includes three segments: supporting coils, filter, and leading coils.&#xD;
The device is available in sizes of 6.0mm - 10.0mm (in 0.5mm intervals) to accommodate individual CCA diameters</description>
    <arm_group_label>Vine™ implantation bilaterally in the common carotid arteries</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Atrial fibrillation (AF): documented persistent or permanent&#xD;
&#xD;
          2. CHA2DS2-VASc score ≥ 4&#xD;
&#xD;
          3. Age &gt; 50&#xD;
&#xD;
          4. Unsuitable for oral anticoagulation therapy (OAC), defined as contraindicated for OAC,&#xD;
             patient refusing OAC, or physician is reluctant to prescribe OAC&#xD;
&#xD;
          5. Maximal (systolic) CCA diameter range: ≥ 5.3mm and ≤ 9.8mm&#xD;
&#xD;
          6. CCA accessibility: up to 60mm from skin to CCA center, safe approach&#xD;
&#xD;
          7. Patient is willing to provide informed consent&#xD;
&#xD;
          8. Patient is willing to complete all scheduled follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of carotid stenosis &gt; 30% [CCA, internal carotid artery (ICA), or external&#xD;
             carotid artery (ECA)&#xD;
&#xD;
          2. Evidence of any atherosclerotic disease in CCA above the clavicles&#xD;
&#xD;
          3. Evidence of carotid dissection&#xD;
&#xD;
          4. Pre-existing stent(s) in CCA&#xD;
&#xD;
          5. Contraindicated or allergic to antiplatelet therapy, or any medication required during&#xD;
             the study&#xD;
&#xD;
          6. Recent stroke, TIA, or myocardial infarction (MI) within two months prior to index&#xD;
             procedure&#xD;
&#xD;
          7. Female who is pregnant or who is planning to become pregnant during the course of the&#xD;
             study&#xD;
&#xD;
          8. Life expectancy of less than 1 year&#xD;
&#xD;
          9. Active systemic infection&#xD;
&#xD;
         10. Known sensitivity to nickel or titanium metals, or their alloys&#xD;
&#xD;
         11. Known hereditary or acquired coagulation disorders&#xD;
&#xD;
         12. Any planned surgical or endovascular procedure within 14 days prior to or 30 days&#xD;
             after the index procedure&#xD;
&#xD;
         13. A co-morbid disease or condition that could confound the neurological and functional&#xD;
             evaluations or compromise survival or ability to complete follow-up assessments&#xD;
&#xD;
         14. Current use or a recent history of illicit drug(s) use or alcohol abuse (defined as&#xD;
             regular or daily consumption of more than four alcoholic drinks per day)&#xD;
&#xD;
         15. Active participation in another investigational drug or device treatment study&#xD;
&#xD;
         16. Any other condition that in the opinion of the investigator may adversely affect the&#xD;
             safety of the subject or would limit the subject's ability to complete the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petr Neuzil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Na Homolca Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Van der Heijden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Antonius Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tom De Potter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OLV Ziekenhuis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan Verheye, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ZNA Stuivenberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OLV Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZNA Stuivenberg</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint-Antonius ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 30, 2018</study_first_submitted>
  <study_first_submitted_qc>June 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2018</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

